Biological pathways associated with the development of pulmonary toxicities in mesothelioma patients treated with radical hemithoracic radiation therapy

The study included individuals with MPM, treated with lung-sparing surgery and neoadjuvant chemotherapy, followed by RHR with curative intent, and followed up prospectively for development of pulmonary toxicity. Due to the strong impact of grade 3 pulmonary toxicities on the quality of life, compared to less serious adverse events, for genetic analyses patients were divided into a none or tolerable pulmonary toxicity (NoSTox) group (Grade lower than 2) and a severe pulmonary toxicity (Stox) group (Grade equals to 3).